Click here to return to the main webpage for the IBTA.
IBTA October 2009 E-News
Dear friend of the international brain tumour community
Awareness Week and World Walk: The International Brain Tumour Awareness Week (1-7 November) is almost upon us. We wish to thank the record number of 176 brain tumour and cancer-related organisations who have supported the IBTA’s Week and Walk this year. Dozens of events have been planned (see: www.theibta.org) . With a combined total of 150,598 walking kms achieved to date we are in sight of our World Walk target of 200,000 kms (five times around the World at the Equator).
Please use the occasion of the International Week to issue a media statement in your area drawing attention to the need for more research and support to combat brain tumours. An additional news aspect you could mention is that November this year represents the 125th anniversary of the first documented, modern-day brain tumour surgery for a glioma, performed by Rickman Godlee in London on 25 November 1884 (see the IBTA’s booklet about the subject).
ECCO/ESMO: The
IBTA had a display at and was represented by Kathy Oliver (Co-Director) and
Denis Strangman (Chair) at the Joint ECCO 15 – 34th ESMO
Multidisciplinary Congress at
Mike Traynor: The IBTA was shocked and saddened to learn
recently of the death of Mike Traynor, Co-Founder and President of the Pediatric Brain Tumor Foundation of the
Scott Norris:
Scott has a GBM and in 2007 he returned to the
Automatic translation widget survey: Thank you to the 66 contacts with multi-language skills who evaluated the automatic translation program that we included on our website for a short time. We regret to advise that their conclusions about the translated versions were generally “poor” to “average” and we have now removed the program. For example, here was one comment: “ … Walk Around the World for Brain Tumours translated as "Todo el mundo a pie para tumores de cerebro" is dangerously wrong. The Spanish version, literally says "Everybody stand up for Brain Tumors" !”. Another comment was: “The translator does not work well for Slavic Languages”. See here for other comments.
We will conduct another survey soon regarding the date for the Awareness Week in 2010. Please respond with your views. We realise that some countries have different dates for their own national/regional awareness days/weeks/months. The IBTA’s week enables an opportunity for international collaboration and unity on a second occasion during the year.
In 2010 we plan to publish a one-off magazine-type publication aimed at brain tumour patients and
families who are visiting the waiting room of a treatment centre. It will be
“popularly” designed and presented, along the lines of magazines that one
typically finds in a medical waiting room (but not as ancient as some!). It
will contain stories about patients, researchers, clinicians, treatment
developments, clinical trials, awareness-raising events, etc. The title needs
to be all-encompassing, relevant and catchy but not off-putting. Please convey your suggestions for a suitable
title and we will include them in a poll of our 3,500 international contacts.
Avastin: A short article by Drs Michael Weller and Roger Stupp “Approval of new drugs for glioblastoma” is available in PDF format from the journal Current Opinion in Neurology. It concludes with a mention of the possible disadvantages of bevacizumab (Avastin) for glioma. Meanwhile, Roche issued a media statement on 22 September based around the findings of Professor James Vredenburg from Duke, reported at the ECCO/ESMO meeting, in the BRAIN Phase II study which showed possible stablilisation or improvement in neurocongitive function and a reduction in the use of steroids for relapsed or progressive glioblastoma.
Italy: Dr Andrea Pace has advised that there
will be another brain tumour awareness raising 5 kms run in
EPPOSI (European Platform for Patients' Organisations, Science and Industry) will hold its "10th Workshop on Partnering for Rare Disease Therapy Development" in the Belgian Federal Parliament building on Monday, 26th and Tuesday, 27th October. As part of this two-day conference, there will be a half-day session on "Rare Cancers". Kathy Oliver (IBTA Co-Director) will be speaking in this session on the patient and caregiver perspective of health technology assessments (HTA). While visiting the US National Brain Tumor Society (NBTS) recently IBTA Chair Denis Strangman discussed the concept of rare cancers with Deputy Executive Director Mark Cole. Mark is engaged in work relating to what is described as the “lethal cancers” (which includes lung and brain). Other people use terms such as “intransigent” or “less common” cancers for those that need particular attention.
Hong Kong: Dr
Danny Chan advises that he and his associates will organise another Brain
Trekking awareness-raising walk in
Partnership: On
29 September 2009, more than 300 cancer organisations, patients and cancer
survivors, health professionals, researchers, health authorities and health
ministers gathered in
Marguerite Sciuk:
It is with deep sorrow that the IBTA learned of the untimely death on 29
September of Marguerite Sciuk, Founder and President of the Brain Tumor Resource and Information
Network (B.R.A.I.N.) in the
North America: IBTA Chair Denis Strangman attended and
spoke briefly at the Brain Tumor
Advanced Treatments Conference held in
While on the West
Coast Denis also met with Mark Cole (Deputy Executive Director), Mary Lovely
and Sharon Lamb from the National
Brain Tumor Society and visited officials from the Amgen company and from the distributors of the
stereotactic radiosurgery device CyberKnife (Accuray)
and its inventor Dr John Adler
at Stanford University Medical Center. Interestingly, Stanford has a sign in
the Center pointing to where patients may connect with their trained volunteer “patient
navigator”. This is a concept that could be copied elsewhere.
Grandma Pat: This might be an unusual title but it
refers to a long-term GBM survivor (8 years) “Pat” in the
Brain screening: A study
in the British Medical Journal, involving the analysis of almost 20,000 brain
scans, concluded that brain screening for health reasons is not justified,
despite the identification of incidental findings of 2.7% on brain MRI. The
IBTA has embarked on a major task of informing our colleagues in the cancer
control movement that an emphasis on screening, early detection and prevention,
is just not relevant to priorities in trying to combat brain tumours. Our
immediate needs involve more research funding and better patient and family
support. We understand that our friends at Methodist University
Hospital at
Professor Abhijit Guha: Ab Guha, former Chair of SNO, had many
friends around the world concerned for his health and welfare after he
developed a challenging illness. We heard that he was much better and asked if
we could report this. Ab responded: “Please do mention and give my thanks to
all for their friendship and support”.
Thank you for your continuing support.
Denis Strangman (Chair and
Co-Director)
International Brain Tumour Alliance IBTA
www.theibta.org
Kathy Oliver (Co-Director)
PO Box 244, Tadworth, Surrey
KT20 5WQ, United Kingdom
Tel:+ (44) + (0) + 1737 813872
Fax: + (44) + (0) +1737 812712
Mob: + (44) + (0) + 777 571 2569
The International Brain Tumour Alliance is a not-for-profit, limited liability
company registered in England and Wales, registered number 6031485. Registered office: Roxburghe House,
Note: This e-mail has been sent to hidden e-mail addresses to protect personal
information. If you do not know why you have been sent it, or would prefer not
to receive such e-mails in the future, please contact: chair@theibta.org